Case Studies  /  Pharma

Pharma & Life Sciences · Global Manufacturer · 6 Sites

Eliminating $64M in Batch Failures & FDA 483 Remediation

A global pharmaceutical manufacturer faced $22M per batch failure in write-offs plus $4M each in FDA 483 observation remediation. CAPA cycles averaged 90 days with no causal link between deviations — until Causeloop traced every failure to upstream equipment calibration drift.

$64M
Annual savings realized
68%
CAPA cycle reduction
0
FDA 483s in year 2
Quality Risk Intelligence — PharmaGlobal Inc.AI · Live
3
Open 483s
$22M
Batch at risk
7
Active deviations
29d
Avg CAPA now
Batch PGA-4412 — sterility assurance deviationROOT CAUSE$22M risk
Lyophilizer calibration drift — Site 3PATTERN · 4 batches$18M
API potency OOS — excipient vendor changeROOT CAUSE$8M risk
AI Root Cause: 4 batch failures at Site 3 share a single causal chain — lyophilizer shelf temperature calibration drifted +2.3°C starting Day 91 post-last-PM. Matches all 4 sterility deviation profiles.
The Business Problem

$22M Every Time a Batch Fails — With No Causal Link

The CAPA system had thousands of deviations open, but no intelligence connecting them. Each investigation was siloed. Every batch failure came as a complete surprise.

Before Causeloop

The CAPA Labyrinth

90-day average CAPA cycle. Root cause investigations were document-heavy, manually cross-referenced across LIMS, QMS, EBR, and maintenance systems — none of which talked to each other.

3 FDA 483 observations in 2023 — each $4M in remediation costs plus reputational exposure. The observations were for repeat deviations that had occurred 6 months earlier but were never connected.

Lyophilizer calibration drift at Site 3 caused 4 batch failures over 6 months ($88M in write-offs) before anyone realized it was the same equipment, the same drift, the same root cause.

No predictive signal. The quality team was entirely reactive — reviewing deviations after the batch was already lost, with no ability to intervene before failure.

$88M
Batch failures (2023)
3
FDA 483s
90 days
Avg CAPA cycle
After Causeloop

Predictive Quality, Audit-Ready CAPAs

29-day average CAPA cycle — a 68% reduction. Causeloop auto-generates the causal chain, surfaces the affected systems, and pre-populates the CAPA document with evidence.

Zero FDA 483s in year 2. Repeat deviation patterns are now surfaced before the next audit. The manufacturer demonstrated to FDA that systemic issues were identified and resolved proactively.

Batch failure predicted 8 days early. Lyophilizer drift at Site 3 was flagged by Causeloop after the second batch — preventing batches 3 and 4 from ever being started. Saved $44M.

Cross-site deviation sharing. Causeloop identified the same lyophilizer drift pattern at Site 5 — before a single batch failed there — using the causal model from Site 3.

$24M
Batch failures (post)
0
FDA 483s (year 2)
29 days
Avg CAPA cycle
Causal Intelligence

One Thermometer. Four Batch Failures. $88M.

The lyophilizer shelf temperature drift started at +0.3°C — well within the SPC control chart warning limits. By the time it became visible in standard QC, four batches worth $88M were already lost.

Root Cause
Lyophilizer Calibration Drift
Shelf temperature thermocouple drifted +2.3°C from setpoint over 14 weeks. IQOQ certificate expired — calibration deferred in backlog.
+2.3°C drift
Detection Gap
SPC Threshold Miss
Standard ±5°C SPC limit never breached. Process capability (Cpk) trended down over 14 weeks — visible in retrospect, not flagged in real time.
14 weeks silent
Downstream Effect
Shelf Temp Excursion
Actual shelf temperature consistently above setpoint. Product moisture content exceeds 3.2% specification threshold across all affected batches.
Moisture >3.2%
Escalation
4 Batch Failures & 3 FDA 483s
QC release testing fails on 4 consecutive batches. FDA inspection surfaces 3 observations: calibration program deficiency, CAPA inadequacy, trend analysis gap.
3 FDA 483s
Financial Impact
$88M Batch Write-offs
4 batches × $22M = $88M in COGS write-off, plus $4M per FDA 483 remediation, plus consent decree risk on the manufacturing site.
$88M
End-to-End Platform Flow

From Lyophilizer Drift to Audit-Ready CAPA

How Causeloop traced 4 batch failures to a single calibration gap — and closed it before FDA noticed.

Ingest

LIMS, QMS, EBR (electronic batch records), SCADA, and maintenance CMMS unified across all 6 manufacturing sites globally.

6 sites · real-time

Detect Deviations

LIMS anomaly in shelf temperature logged on Day 1 of the drift. Correlated to 3 prior deviations across batches PGA-4410, -4411, -4412 automatically.

Day-1 signal

Trace Root Cause

Causal chain: PM schedule gap → lyophilizer calibration drift (+2.3°C) → shelf temp excursion → sterility deviation → batch failure. Cross-site pattern confirmed.

Full chain · cross-site

Auto-Generate CAPA

CAPA document pre-populated with full causal evidence, affected batches, corrective actions, and effectiveness check schedule. FDA-ready in 2 hours.

29-day cycle avg

Cross-Site Learning

Site 5 lyophilizer flagged using Site 3 causal model — before a single failure there. The loop is broken across the entire manufacturing network.

$44M prevented
"We spent three years trying to make our CAPA process faster. Causeloop didn't speed up the process — it changed what the process does. Instead of investigating after the fact, we're now preventing the deviation from repeating. Our FDA relationship has never been better."
VP of Global Quality · Top-20 Pharma Manufacturer (name withheld per NDA)
Measurable Results

12 Months of Quality Intelligence

Causeloop connected all 6 manufacturing sites in 26 days. One year later, the quality team had transformed from reactive investigators to predictive guardians.

$64M

Annual savings realized

Batch failure prevention ($44M from 2 avoided failures) + CAPA labor reduction ($8M) + FDA 483 remediation avoided ($12M).

68%

CAPA cycle reduction

From 90 days to 29 days on average. Auto-generated causal evidence packages eliminated 60% of the manual investigation work.

Zero

FDA 483 observations (year 2)

After 3 observations in 2023, the manufacturer received zero in 2024. FDA acknowledged the systemic quality improvement in the EIR.

8 days

Average batch failure lead time

Causeloop now predicts batch quality outcomes 5–12 days before the batch is released — enabling intervention before failure, not after.

6 sites

Cross-site pattern sharing

Causal models from one site now automatically propagate to all 6. Site 5 avoided $22M in failures using the Site 3 lyophilizer model.

8.4×

First-year ROI

At $7.6M annual platform investment, the manufacturer realized 8.4× ROI. The quality team is now expanding Causeloop to all 14 global sites.

See Your Quality Deviation Root Causes

Connect your LIMS, QMS, and EBR systems. In 48 hours, Causeloop maps the causal chains behind your open deviations — and shows you how many are the same root cause wearing different masks.

Get a free quality assessment View all case studies